Erratum: Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver (American Society for Clinical Investigation (2015) 125:12 (4447-4462) DOI: 10.1172/JCI82204);Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver

Journal of Clinical Investigation

Volumn 125, Issue 12, 2015, Pages 4447-4462

  Satapati, Santhosh ^a   Kucejova, Blanka ^a   Duarte, Joao A G ^a   Fletcher, Justin A ^a   Reynolds, Lacy ^a   Sunny, Nishanth E ^a   He, Tianteng ^a   Arya Nair, L ^a   Livingston, Kenneth ^a   Fu, Xiaorong ^a   Merritt, Matthew E ^a   Dean Sherry, A ^a   Malloy, Craig R ^a   Shelton, John M ^a   Lambert, Jennifer ^a   Parks, Elizabeth J ^b   Corbin, Ian ^a   Magnuson, Mark A ^c   Browning, Jeffrey D ^a   Burgess, Shawn C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOENOLPYRUVATE CARBOXYKINASE 1; UNCLASSIFIED DRUG; PHOSPHOENOLPYRUVATE CARBOXYKINASE 1 (SOLUBLE) PROTEIN, RAT; SIGNAL PEPTIDE;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FATTY LIVER; GLUCONEOGENESIS; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIPID DIET; LIVER BIOPSY; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ANIMAL; INFLAMMATION; LIVER CELL; LIVER MITOCHONDRION; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; HEPATOCYTES; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MITOCHONDRIA, LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RATS; RATS, WISTAR;

EID: 84948799410     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI86695     Document Type: Erratum

References (68)

1. Owen OE, Kalhan SC, Hanson RW. The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem. 2002;277(34):30409-30412.
2. Basu R, et al. Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia. J Clin Endocrinol Metab. 2013;98(3):E409-E417.
3. Beylot M, Soloviev MV, David F, Landau BR, Brunengraber H. Tracing hepatic gluconeogene-sis relative to citric acid cycle activity in vitro and in vivo. Comparisons in the use of [3-13C]lactate, [2-13C]acetate, and α-keto[3-13C]isocaproate. J Biol Chem. 1995;270(4):1509-1514.
4. Walter P, Paetkau V, Lardy HA. Paths of carbon in gluconeogenesis and lipogenesis. 3. The role and regulation of mitochondrial processes involved in supplying precursors of phosphoenolpyruvate. J Biol Chem. 1966;241(11):2523-2532.
5. Chakravarty K, Cassuto H, Reshef L, Hanson RW, Cox MM. Factors that control the tissue-specific transcription of the gene for phospho-enolpyruvate carboxykinase-C. Crit Rev Biochem Mol Biol. 2005;40(3):129-154.
6. Pilkis SJ, Granner DK. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol. 1992;54:885-909.
7. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011;14(6):804-810.
8. Hakimi P, et al. Phosphoenolpyruvate carboxyki-nase and the critical role of cataplerosis in the control of hepatic metabolism. Nutr Metab (Lond). 2005;2:33.
9. Adina-Zada A, Zeczycki TN, St Maurice M, Jitra-pakdee S, Cleland WW, Attwood PV. Allosteric regulation of the biotin-dependent enzyme pyruvate carboxylase by acetyl-CoA. Biochem Soc Trans. 2012;40(3):567-572.
10. Williamson JR, Scholz R, Browning ET. Control mechanisms of gluconeogenesis and ketogen-esis. II. Interactions between fatty acid oxidation and the citric acid cycle in perfused rat liver. J Biol Chem. 1969;244(17):4617-4627.
11. Williamson JR, Cooper RH. Regulation of the citric acid cycle in mammalian systems. FEBS Lett. 1980;117(suppl):K73-K85.
12. Begriche K, Massart J, Robin M-A, Bonnet F, Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013;58(4):1497-1507.
13. Satapati S, et al. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res. 2012;53(6):1080-1092.
14. Mantena SK, et al. High fat diet induces dys-regulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J. 2009;417(1):183-193.
15. Rector RS, et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol. 2010;52(5):727-736.
16. 14 C-labeled propionate metabolism in vivo and estimates of hepatic gluconeogenesis relative to Krebs cycle flux. Am J Physiol. 1993;265(4 pt 1):E636-E647.
17. Jones JG, Solomon MA, Cole SM, Sherry AD, Malloy CR. An integrated (2)H and (13)C NMR study of gluconeogenesis and TCA cycle flux in humans. Am J Physiol Endocrinol Metab. 2001;281(4):E848-E856.
18. Jin ES, Jones JG, Merritt M, Burgess SC, Malloy CR, Sherry AD. Glucose production, gluconeo-genesis, and hepatic tricarboxylic acid cycle fluxes measured by nuclear magnetic resonance analysis of a single glucose derivative. Anal Bio-chem. 2004;327(2):149-155.
19. Magnusson I, et al. Noninvasive tracing of Krebs cycle metabolism in liver. J Biol Chem. 1991;266(11):6975-6984.
20. Di Donato L, Des Rosiers C, Montgomery JA, David F, Garneau M, Brunengraber H. Rates of gluconeogenesis and citric acid cycle in perfused livers, assessed from the mass spectrometric assay of the 13C labeling pattern of glutamate. J Biol Chem. 1993;268(6):4170-4180.
21. Befroy DE, et al. Direct assessment of hepatic mitochondrial oxidative and anaplerotic fluxes in humans using dynamic 13C magnetic resonance spectroscopy. Nat Med. 2014;20(1):98-102.
22. Hasenour CM, et al. Mass spectrometry-based microassay of 2H and 13C plasma glucose labeling to quantify liver metabolic fluxes in vivo. Am J Physiol Endocrinol Metab. 2015;309(2):E191-E203.
23. Petersen KF, Blair JB, Shulman GI. Triiodothy-ronine treatment increases substrate cycling between pyruvate carboxylase and malic enzyme in perfused rat liver. Metabolism. 1995;44(11):1380-1383.
24. Roden M, et al. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes. 2000;49(5):701-707.
25. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417(1):1-13.
26. Egnatchik RA, Leamy AK, Jacobson DA, Shiota M, Young JD. ER calcium release promotes mito-chondrial dysfunction and hepatic cell lipotoxic-ity in response to palmitate overload. Mol Metab. 2014;3(5):544-553.
27. She P, Shiota M, Shelton KD, Chalkley R, Postic C, Magnuson MA. Phosphoenolpyruvate carboxykinase is necessary for the integration of hepatic energy metabolism. Mol Cell Biol. 2000;20(17):6508-6517.
28. Burgess SC, et al. Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab. 2007;5(4):313-320.
29. Berry MN, Williamson DH, Wilson MB. Concentrations of acetoacetate and d-(-)-3-hydroxybutyrate in rat liver and blood. Biochem J. 1965;94:17C-19C.
30. Bergman C, Kashiwaya Y, Veech RL. The effect of pH and free Mg2+ on ATP linked enzymes and the calculation of Gibbs free energy of ATP hydrolysis. J Phys Chem B. 2010;114(49):16137-16146.
31. Sato K, et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J. 1995;9(8):651-658.
32. Krebs HA, Veech RL. Equilibrium relations between pyridine nucleotides and adenine nucle-otides and their roles in the regulation of metabolic processes. Adv Enzyme Regul. 1969;7:397-413.
33. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143-156.
34. Kleiner DE, et al. Design and validation of a his-tological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-1321.
35. Ishak K, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696-699.
36. Cheng Z, et al. Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat Med. 2009;15(11):1307-1311.
37. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalco-holic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol. 2008;14(2):193-199.
38. Koliaki C, Roden M. Hepatic energy metabolism in human diabetes mellitus, obesity and nonalcoholic fatty liver disease. Mol Cell Endocrinol. 2013;379(1-2):35-42.
39. Felig P, Wahren J, Hendler R, Brundin T. Splanchnic glucose and amino acid metabolism in obesity. J Clin Invest. 1974;53(2):582-590.
40. Koliaki C, et al. Adaptation of hepatic mitochon-drial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015;21(5):739-746.
41. Rector RS, et al. Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect. Hepa-tology. 2013;57(6):2213-2223.
42. Satapati S, et al. Partial resistance to peroxi-some proliferator-activated receptor-alpha agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism. Diabetes. 2008;57(8):2012-2021.
43. Cotter DG, et al. Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia. J Clin Invest. 2014;124(12):5175-5190.
44. Iozzo P, et al. Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroen terology. 2010;139(3):846-856.e846.
45. Burgess SC, et al. Impaired tricarboxylic acid cycle activity in mouse livers lacking cytosolic phosphoenolpyruvate carboxykinase. J Biol Chem. 2004;279(47):48941-48949.
46. Owen MR, Halestrap AP. The mechanisms by which mild respiratory chain inhibitors inhibit hepatic gluconeogenesis. Biochim Biophys Acta. 1993;1142(1-2):11-22.
47. Hasenour CM, Berglund ED, Wasserman DH. Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver. Mol Cell Endocrinol. 2013;366(2):152-162.
48. Moreno-Sanchez R, et al. Reactive oxygen species are generated by the respiratory complex II-evidence for lack of contribution of the reverse electron flow in complex I. FEBS J. 2013;280(3):927-938.
49. Quinlan CL, Goncalves RL, Hey-Mogensen M, Yadava N, Bunik VI, Brand MD. The 2-oxoacid dehydrogenase complexes in mitochondria can produce superoxide/hydrogen peroxide at much higher rates than complex I. J Biol Chem. 2014;289(12):8312-8325.
50. Gao D, et al. The effects of palmitate on hepatic insulin resistance are mediated by NADPH Oxi-dase 3-derived reactive oxygen species through JNK and p38MAPK pathways. J Biol Chem. 2010;285(39):29965-29973.
51. Nakamura S, et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J Biol Chem. 2009;284(22):14809-14818.
52. Egnatchik RA, Leamy AK, Noguchi Y, Shiota M, Young JD. Palmitate-induced activation of mitochondrial metabolism promotes oxidative stress and apoptosis in H4IIEC3 rat hepatocytes. Metabolism. 2014;63(2):283-295.
53. Fisher-Wellman KH, Neufer PD. Linking mito-chondrial bioenergetics to insulin resistance via redox biology. Trends Endocrinol Metab. 2012;23(3):142-153.
54. Treberg JR, Quinlan CL, Brand MD. Evidence for two sites of superoxide production by mitochon-drial NADH-ubiquinone oxidoreductase (complex I). J Biol Chem. 2011;286(31):27103-27110.
55. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007;28(12):551-558.
56. Xu Z, Chen L, Leung L, Yen TS, Lee C, Chan JY. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci USA. 2005;102(11):4120-4125.
57. Vomhof-Dekrey EE, Picklo MJ Sr. The Nrf2-anti-oxidant response element pathway: a target for regulating energy metabolism. J Nutr Biochem. 2012;23(10):1201-1206.
58. Huang LJ, Chuang IC, Dong HP, Yang RC. Hypoxia-inducible factor 1alpha regulates the expression of the mitochondrial ATPase inhibitor protein (IF1) in rat liver. Shock. 2011;36(1):90-96.
59. Gomez-Valades AG, et al. Overcoming diabetesinduced hyperglycemia through inhibition of hepatic phosphoenolpyruvate carboxykinase (GTP) with RNAi. Mol Ther. 2006;13(2):401-410.
60. Sun Y, et al. Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgen-ic mice. J Biol Chem. 2002;277(26):23301-23307.
61. Chawla A, Nguyen KD, Goh YPS. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011;11(11):738-749.
62. Burgess SC, et al. Effect of murine strain on metabolic pathways of glucose production after brief or prolonged fasting. Am J Physiol Endocrinol Metab. 2005;289(1):E53-E61.
63. Sunny NE, et al. Progressive adaptation of hepatic ketogenesis in mice fed a high-fat diet. Am J Physi-ol Endocrinol Metab. 2010;298(6):E1226-E1235.
64. Jones JG, Naidoo R, Sherry AD, Jeffrey FMH, Cottam GL, Malloy CR. Measurement of glu-coneogensis and pyruvate recycling in the rat liver: a simple analysis of glucose and glutamate isotopomers during metabolism of [1, 2, 3-13C3] propionate. FEBS Lett. 1997;412(1):131-137.
65. Malloy CR, Jones JG, Jeffrey FM, Jessen ME, Sherry AD. Contribution of various substrates to total citric acid cycle flux and anaplerosis as determined by 13C isotopomer analysis and O2 consumption in the heart. MAGMA. 1996;4(1):35-46.
66. Desrosiers C, Fernandez CA, David F, Brunengra-ber H. Reversibility of the mitochondrial isoci-trate dehydrogenase reaction in the perfused rat liver. J Biol Chem. 1994;269(44):27179-27182.
67. Burgess SC, et al. Diminished hepatic gluconeo-genesis via defects in tricarboxylic acid cycle flux in peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1α)-deficient mice. J Biol Chem. 2006;281(28):19000-19008.
68. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3):726-735.